Trying to separate three different claims about liraglutide: that it is the right molecule, that it is the right dose, and that it does something useful.
What surprised me is how much of the perceived benefit was routine and attention rather than pharmacology.
The effect size I actually noticed is roughly a third of what the write-ups imply, and it took four months to be sure.
The animal data is stronger than the human data and the human data is not nothing, it is just small.
Titration is slow by design and rushing it is how people end up miserable.
Anyone got a paper worth reading on this rather than a write-up of a paper?
Baseline first. Not on liraglutide but the pattern is familiar.
Read the methods section. It is the only part that says whether the conclusion is allowed to exist.
Log dose, time and sleep. Ten seconds a day and it turns the anecdote into something you can look at.
Nobody has ever been talked out of a stack by a stranger on the internet. Four months in on liraglutide and it lines up.
Log dose, time and sleep. Ten seconds a day and it turns the anecdote into something you can look at.
Most of the popular protocol is borrowed from a clinical population and applied to healthy people without comment.
Read the methods section. It is the only part that says whether the conclusion is allowed to exist. Currently on liraglutide myself.
Where does the human data stop and the extrapolation begin? That is the whole thread.
Stupid question: how do you know whether what is in the vial matches the label at all?
An inconclusive account is useful if it stops the next person mistaking a story for a controlled comparison.
Narrow conclusion, briefly right. Broad conclusion, interestingly wrong. I know which I keep choosing. Same for me with liraglutide, unfortunately.
Baseline first.
Stupid question: how do you know whether what is in the vial matches the label at all?
An inconclusive account is useful if it stops the next person mistaking a story for a controlled comparison.